Deliver Therapeutics utilizes high-throughput DNA-encoded library screening to identify novel small molecule therapeutics targeting key tyrosine kinases, addressing the critical issue of cancer drug resistance. The company is developing a multi-kinase inhibitor that demonstrates significantly improved efficacy against resistant cancer cell lines compared to existing treatments.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Resistance to first-line kinase inhibitors often leads to cancer recurrence and poor prognosis, representing a critical unmet medical need. Current treatments may also have significant adverse effects, limiting their long-term use.
Solution
Deliver Therapeutics is developing novel small molecule therapeutics that target key tyrosine kinases to overcome cancer drug resistance. The company utilizes high-throughput DNA-encoded library (DEL) screening to identify best-in-class and first-in-class drug candidates. Their lead product is a multi-kinase inhibitor with single-digit nanomolar IC50 values against ABL1-T315I, BTK, AurK, JAK, and LCK. This multi-kinase inhibitor has demonstrated significantly improved efficacy against resistant Ph+ ALL patient-derived tumor cell lines compared to existing treatments, such as ponatinib. Deliver Therapeutics is also developing selective JAK2, JAK2/3, and TYK2/JAK3 inhibitors as senomorphic therapies to down-regulate the senescence-associated secretory phenotype (SASP) without the adverse effects of JAK1 inhibition.
Target Audience
The primary target audience includes patients with Ph+ Acute Lymphocytic Leukemia (Ph+ ALL) and Ph+ "Like" ALL, as well as individuals with age-related diseases linked to cellular senescence and SASP.
Features
- High-throughput DNA-encoded library (DEL) screening platform for identifying novel small molecule kinase inhibitors.
- Multi-kinase inhibitor targeting ABL1-T315I, BTK, AurK, JAK, and LCK with single-digit nanomolar IC50 values.
- Demonstrated superior efficacy against resistant Ph+ ALL patient-derived tumor cell lines compared to ponatinib.
- Selective JAK2, JAK2/3, and TYK2/JAK3 inhibitors for senomorphic therapy.
- Topical and systemically-delivered formulations for senomorphic therapies.